Status:
COMPLETED
A Phase II Study of Cetuximab Plus Irinotecan in Patients With EGFR-detectable Metastatic Colorectal Carcinoma
Lead Sponsor:
Eli Lilly and Company
Conditions:
Colorectal Carcinoma
Eligibility:
All Genders
20-75 years
Phase:
PHASE2
Brief Summary
To evaluate the response rate of cetuximab plus irinotecan combination therapy in subjects with EGFR-detectable metastatic colorectal carcinoma who have documented progressive disease to irinotecan-ba...
Eligibility Criteria
Inclusion
- The subject must have surgically unresectable metastatic colorectal carcinoma.
- The subjects who have received and failed Ilinotecan, oxaliplatin and fluoropyrimidine-based chemotherapy
- ECOG PS 0-2
Exclusion
- Subjects with symptomatic cerebral metastasis
Key Trial Info
Start Date :
October 1 2005
Trial Type :
INTERVENTIONAL
End Date :
July 1 2006
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT00362102
Start Date
October 1 2005
End Date
July 1 2006
Last Update
November 22 2016
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.